DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Rugo HS, Im S-A, Cardoso F. et al.
Phase 3 SOPHIA study of margetuximab + chemotherapy vs. trastuzumab + chemotherapy in patients with HER2+ metastatic breast cancer after prior anti-HER2 therapies: second interim overall survival analysis.
San Antonio Breast Cancer Symposium 2019;
2019: GS1-02
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.